Growth differentiation factor-15 combined with N-terminal prohormone of brain natriuretic peptide increase 1-year prognosis prediction value for patients with acute heart failure
Open Access
- 5 October 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 132 (19) , 2278-2285
Abstract
Clinical assessment and treatment guidance for heart failure depends on a variety of biomarkers. The objective of this study was to investigate the prognostic predictive value of growth differentiation factor-15 (GDF-15) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) in assessing hospitalized patients with acute heart failure (AHF). In total, 260 patients who were admitted for AHF in the First Affiliated Hospital of Nanjing Medical University were enrolled from April 2012 to May 2016. Medical history and blood samples were collected within 24 h after the admission. The primary endpoint was the all-cause mortality within 1 year. The patients were divided into survival group and death group based on the endpoint. With established mortality risk factors and serum GDF-15 level, receiver-operator characteristic (ROC) analyses were performed. Cox regression analyses were used to further analyze the combination values of NT-proBNP and GDF-15. Baseline GDF-15 and NT-proBNP were significantly higher amongst deceased than those in survivors (P < 0.001). In ROC analyses, area under curve (AUC) for GDF-15 to predict 1-year mortality was 0.707 (95% confidence interval [CI]: 0.648–0.762, P < 0.001), and for NT-proBNP was 0.682 (95% CI: 0.622–0.738, P < 0.001). No statistically significant difference was found between the two markers (P = 0.650). Base on the optimal cut-offs (GDF-15: 4526.0 ng/L; NT-proBNP: 1978.0 ng/L), the combination of GDF-15 and NT-proBNP increased AUC for 1-year mortality prediction (AUC = 0.743, 95% CI: 0.685–0.795, P < 0.001). GDF-15, as a prognostic marker in patients with AHF, is not inferior to NT-proBNP. Combining the two markers could provide an early recognition of high-risk patients and improve the prediction values of AHF long-term prognosis. ChiCTR-ONC-12001944, http://www.chictr.org.cn.Keywords
This publication has 48 references indexed in Scilit:
- Incremental Prognostic Power of Novel Biomarkers (Growth-Differentiation Factor-15, High-Sensitivity C-Reactive Protein, Galectin-3, and High-Sensitivity Troponin-T) in Patients With Advanced Chronic Heart FailureThe American Journal of Cardiology, 2013
- GDF-15 is abundantly expressed in plexiform lesions in patients with pulmonary arterial hypertension and affects proliferation and apoptosis of pulmonary endothelial cellsRespiratory Research, 2011
- Serial Measurement of Growth-Differentiation Factor-15 in Heart FailureCirculation, 2010
- Growth differentiation factor 15 acts anti‐apoptotic and pro‐hypertrophic in adult cardiomyocytesJournal of Cellular Physiology, 2010
- Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapyEuropean Heart Journal, 2009
- Predictive value of N-terminal pro–brain natriuretic peptide in severe sepsis and septic shock*Critical Care Medicine, 2007
- The Transforming Growth Factor-β Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion InjuryCirculation Research, 2006
- GDF15/MIC-1 Functions As a Protective and Antihypertrophic Factor Released From the Myocardium in Association With SMAD Protein ActivationCirculation Research, 2006
- Prognostic Impact of Plasma N-Terminal Pro–Brain Natriuretic Peptide in Severe Chronic Congestive Heart FailureCirculation, 2004
- Diagnostic and prognostic value of plasma brain natriuretic peptide in non—dialysis-dependent CRFAmerican Journal of Kidney Diseases, 2004